Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1971 1
1976 1
1980 3
1981 3
1982 3
1983 2
1984 5
1985 2
1986 3
1987 1
1988 1
1989 1
1991 1
1993 2
1994 2
1995 1
1997 5
1998 7
1999 5
2000 7
2001 3
2002 7
2003 6
2004 10
2005 9
2006 10
2007 13
2008 16
2009 28
2010 29
2011 22
2012 26
2013 17
2014 32
2015 39
2016 43
2017 24
2018 31
2019 43
2020 38
2021 55
2022 44
2023 53
2024 31
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

625 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Among authors: peron jm. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Free PMC article. Clinical Trial.
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D'Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. Bureau C, et al. Among authors: peron jm. Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524293 Clinical Trial.
Recommandations de dépistage en France : une revue systématique.
Yves Meunier P, Maiga K, Maillet D, Bochaton T, De la Fournière B, Delahaye F, Dupont C, Guillaud O, Lamort-Bouché M, Lina B, Ray-Coquard I, Péron J, Letrilliart L. Yves Meunier P, et al. Among authors: peron j. Sante Publique. 2024;36(5):15-35. doi: 10.3917/spub.245.0015. Sante Publique. 2024. PMID: 40402677 French.
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
Larrue H, D'Amico G, Olivas P, Lv Y, Bucsics T, Rudler M, Sauerbruch T, Hernandez-Gea V, Han G, Reiberger T, Thabut D, Vinel JP, Péron JM, García-Pagán JC, Bureau C. Larrue H, et al. Among authors: peron jm. J Hepatol. 2023 Sep;79(3):692-703. doi: 10.1016/j.jhep.2023.04.028. Epub 2023 May 2. J Hepatol. 2023. PMID: 37141993
Consensus Paper: Cerebellum and Reward.
Manto M, Adamaszek M, Apps R, Carlson E, Guarque-Chabrera J, Heleven E, Kakei S, Khodakhah K, Kuo SH, Lin CR, Joshua M, Miquel M, Mitoma H, Larry N, Péron JA, Pickford J, Schutter DJLG, Singh MK, Tan T, Tanaka H, Tsai P, Van Overwalle F, Yamashiro K. Manto M, et al. Among authors: peron ja. Cerebellum. 2024 Oct;23(5):2169-2192. doi: 10.1007/s12311-024-01702-0. Epub 2024 May 20. Cerebellum. 2024. PMID: 38769243 Review.
[Post-COVID-19 neuropsychological syndrome].
Voruz P, Jacot De Alcântara I, Cionca A, Nuber-Champier A, Assal F, Peron JA. Voruz P, et al. Among authors: peron ja. Rev Med Suisse. 2023 Apr 26;19(824):800-802. doi: 10.53738/REVMED.2023.19.824.800. Rev Med Suisse. 2023. PMID: 37133938 French.
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Lau G, et al. Among authors: peron jm. Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385. Online ahead of print. Hepatology. 2025. PMID: 40384092
[Atypical fibroxanthoma].
Péron J, Depaepe L, Decroze D, Jaouen A, Dalle S, Balme B. Péron J, et al. Ann Dermatol Venereol. 2014 Dec;141(12):786-9. doi: 10.1016/j.annder.2014.05.006. Epub 2014 Aug 4. Ann Dermatol Venereol. 2014. PMID: 25433934 Review. French. No abstract available.
Hepatitis E, what's the real issue?
Larrue H, Abravanel F, Péron JM. Larrue H, et al. Among authors: peron jm. Liver Int. 2020 Feb;40 Suppl 1:43-47. doi: 10.1111/liv.14351. Liver Int. 2020. PMID: 32077607 Review.
625 results